SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-013033
Filing Date
2022-05-12
Accepted
2022-05-12 16:10:59
Documents
14
Period of Report
2022-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 39213
2 ex99-1.htm EX-99.1 121594
3 ex99-1_001.jpg GRAPHIC 15767
  Complete submission text file 0001493152-22-013033.txt   370997

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lctx-20220512.xsd EX-101.SCH 3042
5 XBRL LABEL FILE lctx-20220512_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE lctx-20220512_pre.xml EX-101.PRE 22601
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3635
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 22917904
SIC: 2836 Biological Products, (No Diagnostic Substances)